LDN-193189 , ≥98% , 1062368-24-4

CAS NO.：1062368-24-4

Empirical Formula: C25H22N6

Molecular Weight: 406.48

MDL number: MFCD17392570

PRODUCT Properties

• Density: 1.33
• storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• solubility: H2O: soluble5mg/mL, clear (warmed)
• pka: 8.79±0.10(Predicted)
• form: powder
• color: yellow to orange
• Water Solubility: H2O: 5mg/mL, clear (warmed)
• InChI: 1S/C25H22N6.ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;/h1-10,15-17,26H,11-14H2;1H
• InChIKey: XHBVYDAKJHETMP-UHFFFAOYSA-N
• SMILES: C(C=N1)(C2=CC=C(N3CCNCC3)C=C2)=CN4C1=C(C5=CC=NC6=C5C=CC=C6)C=N4.Cl

Description and Uses

Normal development and tissue repair are controlled in part by SMADs, a family of intracellular proteins that are activated by signaling via serine/threonine kinase receptors of the TGF-β superfamily. LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC₅₀ value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC₅₀s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC₅₀s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.

4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, is a selective inhibitor of bone morphogenetic protein (BMP) pathway, useful in the treatment of diseases. Potent BMP Inhibitor, Promotes hPSC Neural Induction.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• WGK Germany: 3
• HS Code: 29339900
• Storage Class: 11 - Combustible Solids